IO生物技术展示了癌症疫苗Cylembio 在ACR, 接受FDA突破治疗指认。 IO Biotech showcases cancer vaccine Cylembio® at AACR, receives FDA Breakthrough Therapy Designation.

以癌症免疫治疗为重点的生物制药公司IO Biotech在2025年ACR年会上突出介绍了其主要癌症疫苗候选者Cylembio。 IO Biotech, a biopharmaceutical company focusing on cancer immunotherapy, highlighted its lead cancer vaccine candidate, Cylembio®, at the 2025 AACR Annual Meeting. 该疫苗获得了林业发展局对高级黑素瘤的“突破治疗”指认。 The vaccine has received Breakthrough Therapy Designation from the FDA for advanced melanoma. IO Biotech公司还宣布计划向另一个疫苗候选者提交调查性新药物应用软件,并获得5 750万欧元的资金,用于推进其研究。 IO Biotech also announced plans to submit an Investigational New Drug Application for another vaccine candidate and secured €57.5 million in financing to advance its research.